Vaccine composition

• US 10,646,557 B2
• Filed: 01/16/2019
• Issued: 05/12/2020
• Est. Priority Date: 02/21/2013
• Status: Active Grant

• Current Assignee: Turnstone Limited Partnership
• Original Assignee: Turnstone Limited Partnership
• Inventors: Stojdl, David F., Bell, John Cameron, Lichty, Brian
• Primary Examiner(s): Foley, Shanon A.
• Assistant Examiner(s): Hill, Myron G
• Application Number:
  US16/249,616
• Publication Number:
  US 20190240301A1
• Time in Patent Office: 482 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/766 Rhabdovirus, e.g. vesicular stomatitis virus
• CPC Class Codes: A61K 39/0005 Vertebrate antigens from snakes A61K39/38
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001184 Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
• CPC Class Codes: A61K 39/001186 MAGE
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/50 containing protease site
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16234 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/20034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/15043 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2760/20223 : Virus like particles [VLP]
• CPC Class Codes: C12N 2760/20232 : Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2760/20242 : virus or viral particle as vehicle, e.g. encapsulating small organic molecule
• CPC Class Codes: C12N 2760/20243 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.

Claims

1. A method of inducing an immune response against a cancer in a mammal, said cancer being a tumour expressing an HPV protein, said method comprising:

a) administering a first virus comprising a nucleic acid capable of expressing an HPV tumour associated antigen, wherein said first virus is capable of generating immunity to said HPV tumour associated antigen;

b) administering a second virus, said second virus being a Vesiculovirus, said second virus comprising a nucleic acid capable of expressing an HPV tumour associated antigen,

wherein said second virus is capable of providing a therapeutic oncolytic effect in said mammal;

wherein said first virus is immunologically distinct and physically isolated from said second virus; and

wherein the amino acid sequence of the HPV tumour associated antigen comprises the amino acid sequence of SEQ ID NO. 7.

2. The method of claim 1, wherein said second virus is Maraba MG1.

3. The method of claim 2, wherein the amino acid sequence of the HPV tumour associated antigen consists of the amino acid sequence of SEQ ID NO:

7.

4. The method of claim 3, wherein the amino acid sequence of the HPV tumour associated antigen is encoded by the nucleotide sequence of SEQ ID NO:

8.

5. The method of claim 4, wherein the Maraba MG1 genome comprises a reverse complement and RNA version of the nucleotide sequence of SEQ ID NO:

9.

6. The method of claim 1, wherein the amino acid sequence of the HPV tumour associated antigen consists of the amino acid sequence of SEQ ID NO:

7.

7. The method of claim 6, wherein the amino acid sequence of the HPV tumour associated antigen is encoded by the nucleotide sequence of SEQ ID NO:

8.

8. The method of claim 1, wherein said first and second virus both express the same HPV tumour associated antigen.

9. The method of claim 1, wherein the cancer expresses HPV E6 or E7 proteins as antigenic proteins.

10. The method of claim 1, wherein the cancer is cervical cancer.

11. The method of claim 1, wherein said first virus is administered intramuscularly.

12. The method of claim 2, wherein said second virus is administered intravenously.

13. The method of claim 12, wherein said first virus is administered intramuscularly.